Strathmore Capital Advisors Inc. Invests $552,000 in Stryker Corporation $SYK

Key Points

• Strathmore Capital Advisors Inc. has acquired a new stake in Stryker Corporation, purchasing 1,408 shares valued at approximately $552,000.
• Insider trading activity includes the sale of 200,000 shares by Director Ronda E. Stryker for $75.29 million, representing a 5.84% decrease in her ownership.
• Stryker reported a quarterly earnings beat with $3.13 EPS, exceeding analyst predictions, and the company announced a quarterly dividend of $0.84 per share.

Strathmore Capital Advisors Inc. bought a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,408 shares of the medical technology company's stock, valued at approximately $552,000.

Several other institutional investors also recently bought and sold shares of the stock. Sunflower Bank N.A. grew its position in Stryker by 4.0% in the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company's stock worth $275,000 after purchasing an additional 27 shares during the last quarter. Continuum Advisory LLC increased its stake in Stryker by 5.8% in the 1st quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company's stock valued at $198,000 after buying an additional 29 shares during the period. Oakworth Capital Inc. grew its position in Stryker by 0.5% in the first quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company's stock worth $2,283,000 after acquiring an additional 29 shares in the last quarter. Strategy Asset Managers LLC boosted its holdings in shares of Stryker by 1.4% during the 1st quarter. Strategy Asset Managers LLC now owns 2,134 shares of the medical technology company's stock worth $794,000 after buying an additional 29 shares during the period. Finally, Tritonpoint Wealth LLC boosted its holdings in Stryker by 0.7% in the 1st quarter. Tritonpoint Wealth LLC now owns 4,042 shares of the medical technology company's stock valued at $1,508,000 after purchasing an additional 30 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on SYK shares. Rothschild & Co Redburn assumed coverage on shares of Stryker in a research report on Thursday. They set a "neutral" rating and a $420.00 target price for the company. Needham & Company LLC upped their price objective on shares of Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a report on Friday, August 1st. Truist Financial set a $415.00 price objective on shares of Stryker and gave the stock a "hold" rating in a research report on Monday, August 4th. Citigroup reissued a "buy" rating and set a $455.00 target price (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, BTIG Research restated a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Fourteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $430.33.

Insider Activity

In related news, insider Viju Menon sold 500 shares of the business's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Stock Down 0.3%

Stryker stock traded down $1.23 on Friday, hitting $376.61. 1,924,253 shares of the stock traded hands, compared to its average volume of 934,259. The business's fifty day simple moving average is $387.52 and its 200 day simple moving average is $379.19. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm has a market cap of $143.98 billion, a P/E ratio of 49.88, a price-to-earnings-growth ratio of 2.72 and a beta of 0.93. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. During the same period in the previous year, the company posted $2.81 EPS. The business's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.